Loading...
ASCO Lung Cancer 20182025-01-27T17:44:01+01:00

ASCO 2018 – Chicago

Lecture Board: Maximilian Hochmair, MD; Bruce E. Johnson, MD; Barbara Melosky, MD
Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from ASCO 2018

memo_InOncology_ASCO_2018_Eng

Full report (english)

memo_InOncology_Spezial_ASCO_2018_mandarin

Full report (mandarin)

ASCO 2018 Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from ASCO 2018

Edward Kim talks about the relevance of biomarkers in choosing patients for immunotherapy and the usefulness/pitfalls pf liquid biopsies.

Barbara Melosky talks about ongoing trials that evaluate afatinib/pembrolizumab combination therapy of squamous-cell carcinoma and potential combinations of anti-EGFR agents with anti-angiogenesis drugs.

Today, nearly half of all patients presenting with advanced lung cancer can receive initial treatment with oral targeted agents or immunotherapy, rather than chemotherapy. I am optimistic that a subset of our lung cancer patients might actually be cured with checkpoint inhibitor therapy. (ASCO 2018)

Bruce E. Johnson • MD •, President, American Society of Clinical Oncology Chief Clinical Research Officer, Dana-Farber Cancer Institute, Boston, MA, USA ASCO Translational Research Professor
Go to Top